Eur Heart J Suppl. 2025 Dec 26;28(Suppl 4):iv16-iv20. doi: 10.1093/eurheartjsupp/suaf094. eCollection 2026 Apr.
ABSTRACT
Tricuspid regurgitation (TR), once considered a passive marker of advanced cardiac disease, is increasingly recognized as an independent contributor to morbidity, mortality, and healthcare burden. Recent evidence, including the pivotal TRILUMINATE trial and Tri-FR, together with supporting cost-effectiveness models, suggest that the correction of TR with T-TEER systems may improve patient outcomes and offer good value for money in European healthcare settings. This article explores the clinical rationale and economic imperative for considering TR as a modifiable and actionable target in modern cardiology ([Adamo M, Chioncel O, Pagnesi M, Bayes-Genis A, Abdelhamid M, Anker SD et al. Epidemiology, pathophysiology, diagnosis and management of chronic right-sided heart failure and tricuspid regurgitation. A clinical consensus statement of the Heart Failure Association (HFA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC. Eur J Heart Fail 2024;26:18-33.]).
PMID:42064866 | PMC:PMC13128260 | DOI:10.1093/eurheartjsupp/suaf094